Abstract
Despite apparent advances in the treatment of hemophilia A, the disease is still treatable but not curable. Coagulation factor VIII substitution has its obvious limitations.
This short article provides a brief overview of the pharmacological properties of emicizumab, a monoclonal antibody with potential for use in hemophilic patients without or with an inhibitor.